CommercialCoverageLow impact
Papzimeos (zopapogene imadenovec-drba)
Blue Cross & Blue Shield of Mississippi·MS · ENT (Ear, Nose & Throat), Pulmonology, Infectious Disease·Medical Policy
Effective date
Apr 1, 2026
We identified it
Jun 20, 2026
Summary
BCBS Mississippi has issued a new policy declaring Papzimeos (zopapogene imadenovec-drba), a new HPV immunotherapy for recurrent respiratory papillomatosis, as not medically necessary. The drug and its administration services will not be covered, and prior authorization will be denied.
Action Required
By April 1, 2026: Billing team must update system to flag HCPCS codes J3404 and J3590 as non-covered for BCBS Mississippi plans when used for Papzimeos. Do not submit claims for this medication as they will be denied. Inform providers that alternative covered treatments should be used for recurrent respiratory papillomatosis.